News | October 11, 2013

Boston Scientific Reports Favorable Clinical Trial Results Assessing The OffRoad Re-Entry Catheter System

OffRoad, CTO, OffRoad CTO Device, Boston Scientific

OffRoad CTO Device

October 11, 2013 – The Boston Scientific OffRoad Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete blockages in the major arteries that supply blood to the legs. These blockages, called chronic total occlusions (CTOs), are often associated with peripheral artery disease (PAD). The data from the Re-ROUTE clinical trial were reported in a late-breaking clinical trial session at the Vascular Interventional Advances Conference (VIVA) in Las Vegas.

In the Re-ROUTE trial, investigators were successful in navigating around challenging CTOs in the enrolled trial patients 84.8 percent of the time using the OffRoad device, exceeding the pre-specified trial goals.

"CTOs in the legs can lead to pain due to lack of blood flow. They also are an indicator of increased risk for major cardiovascular events and can lead to limb amputation and an overall diminished quality of life," said Dr. Andrej Schmidt, Parkhospital Leipzig, Center for Vascular Medicine, Leipzig, Germany, and principal investigator in the Re-ROUTE trial. "In my experience I found the OffRoad System to be a very effective tool for navigating around these challenging blockages, enabling me to treat more patients with peripheral artery disease."

The Re-ROUTE trial is a prospective, single-arm, non-randomized, multicenter (Europe and Canada), post-market study. Results were presented at VIVA 2013 by Dr. Koen Keirse, Regional Hospital Heilig Hart Tienen, Tienen, Belgium. Results included:

  • Investigators achieved an 84.8 percent (78/92) technical success rate using the OffRoad System to cross CTOs in the femoropopliteal arteries.
  • At 30 days post procedure, 75 percent of patients experienced an improvement of at least one category in the Rutherford classification, a six-stage scale commonly used to assess the severity of symptoms associated with PAD.
  • A 3.3 percent device-related major adverse event rate was seen at 30 days, which is below the pre-specified trial goals.

The OffRoad Re-Entry Catheter System includes a balloon catheter with a micro-catheter lancet and is intended to help physicians navigate around complete arterial blockages that might otherwise prevent minimally invasive treatment. The system is designed to pass around the blockage by traveling within the tissue of the vessel wall (subintimal space). Once the catheter has passed the blockage, it re-enters the vessel lumen. A unique conical-shaped positioning balloon is used to expand the subintimal space and direct the micro-catheter lancet to re-enter the lumen. This allows the physician to position a guidewire across the occlusion and treat the blockage using traditional endovascular techniques such as angioplasty and stenting.

The OffRoad Re-Entry Catheter System has received CE Mark approval and is pending U.S. Food and Drug Administration 510(k) clearance. It is currently not available for sale in the United States and data from the Re-ROUTE trial supports U.S. regulatory submissions.

For more information, visit

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init